A Randomized, Double-Blind, Two Way Cross-Over, Proof of Concept Study to Compare the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Two-Week Oral Administration of QAV680 Versus Placebo, With an Extended Open-Label Inhaled Corticosteroid Period, in Steroid-Free, Mild to Moderate Persistent Asthma Patients.

Trial Profile

A Randomized, Double-Blind, Two Way Cross-Over, Proof of Concept Study to Compare the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Two-Week Oral Administration of QAV680 Versus Placebo, With an Extended Open-Label Inhaled Corticosteroid Period, in Steroid-Free, Mild to Moderate Persistent Asthma Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs QAV 680 (Primary) ; Fluticasone propionate
  • Indications Asthma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 21 Apr 2012 New source identified and integrated (EudraCT2008-005168-15: European Clinical Trials Database).
    • 21 Apr 2012 New source identified and integrated (EudraCT2008-005168-15: European Clinical Trials Database).
    • 03 Feb 2011 New source identified and integrated (Clinical Trials Registry - India, CTRI2009-091-000282).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top